Bharat Biotech Partners with Alopexx for Anti-Microbial Vaccine
By Rediff Money Desk, Hyderabad Sep 11, 2024 14:14
Bharat Biotech and Alopexx collaborate to develop and commercialize a broad-spectrum anti-microbial vaccine, AV0328, in India and other low-income countries. The vaccine targets poly N-acetyl glucosamine (PNAG) and aims to combat antimicrobial resistance.
Hyderabad, Sep 11 (PTI) Bharat Biotech on Wednesday announced a collaboration with Alopexx, Inc. for the co-development and commercialisation of the latter's proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low income and lower middle-income countries.
A press release from the city-based vaccine maker said as part of the collaboration, the companies will co-develop and commercialise AV0328, a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), in India and other licensed territories.
Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories, it said.
Krishna Ella, Executive Chairman of Bharat Biotech, said, "We are proud to collaborate with Alopexx to bring AV0328 to the regions where it is most needed. Our goal is to develop solutions to reduce anti-microbial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally."
"This collaboration brings us one step closer to addressing the critical need for affordable, broad-spectrum antimicrobial solutions, especially in low-and middle-income countries," Daniel Vlock, CEO of Alopexx, said.
A press release from the city-based vaccine maker said as part of the collaboration, the companies will co-develop and commercialise AV0328, a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), in India and other licensed territories.
Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories, it said.
Krishna Ella, Executive Chairman of Bharat Biotech, said, "We are proud to collaborate with Alopexx to bring AV0328 to the regions where it is most needed. Our goal is to develop solutions to reduce anti-microbial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally."
"This collaboration brings us one step closer to addressing the critical need for affordable, broad-spectrum antimicrobial solutions, especially in low-and middle-income countries," Daniel Vlock, CEO of Alopexx, said.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- ARC Finance
- 1.51 (+ 2.72)
- 99106131
- Vodafone Idea L
- 8.27 (+ 1.72)
- 37910491
- Guj. Toolroom Lt
- 18.98 (+ 4.98)
- 33052379
- Srestha Finvest
- 0.81 ( -2.41)
- 24087791
- Filatex Fashions
- 0.69 ( -4.17)
- 20455844
MORE NEWS
CCI Clears Coal India in E-Auction Scheme Case
India's competition watchdog CCI dismissed a complaint against Coal India's e-auction...
HDFC Bank Loan Growth Rises 3% in Q3
HDFC Bank reports a 3% increase in loan growth in the December quarter, reaching Rs...
IDBI Bank Reports 18% Loan Growth in Q3
IDBI Bank saw an 18% increase in loan growth during the December quarter, reaching Rs...